Literature DB >> 12651102

Expression, purification, and PC1-mediated processing of human proglucagon, glicentin, and major proglucagon fragment.

Anela Bonic1, Robert B Mackin.   

Abstract

To examine the cleavage specificity of different members of the furin/propeptide convertase (PC) family of enzymes, we have selected proglucagon (PG) as a model substrate. PG was selected because it is subject to differential processing in vivo. PG is thought to be cleaved initially at an interdomain site to produce glicentin and the major proglucagon fragment (MPGF). These intermediates are subsequently cleaved, most likely by the convertases PC2 and PC1, respectively. To determine the exact sites within PG that are cleaved by PC1 and PC2, we attempted to produce milligram quantities of human PG, glicentin, and MPGF for use in an in vitro conversion assay. A methionine residue was added to the N-terminus of each protein to initiate translation. Purification was achieved using cation exchange and reversed-phase chromatography, and the integrity of the methionylated proteins was confirmed by both electrospray ionization-mass spectrometry and amino acid analysis. The combined expression and purification scheme is fast, efficient, and results in milligram quantities of > or =95% pure proglucagon, > or =95% pure MPGF, and > or =93% pure glicentin. These prohormones are cleaved by PC1 to produce product peptides consistent with the processing of PG observed in vivo, and should therefore be suitable for further analysis of the post-translational processing of PG.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651102     DOI: 10.1016/s1046-5928(02)00653-8

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  2 in total

1.  Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.

Authors:  Mirella Vivoli; Thomas R Caulfield; Karina Martínez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

2.  Synthetic small-molecule prohormone convertase 2 inhibitors.

Authors:  Dorota Kowalska; Jin Liu; Jon R Appel; Akihiko Ozawa; Adel Nefzi; Robert B Mackin; Richard A Houghten; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2008-12-12       Impact factor: 4.436

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.